Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding Merck’s supplemental Biologics License Applications seeking to update the dosing frequency for KEYTRUDA, Merck’s anti-PD-1 therapy, to include a 400 mg dose infused over 30 minutes every-six-weeks option in multiple indications.
February 18, 2020
· 29 min read